David A Zaharoff

Summary

Affiliation: University of Arkansas
Country: USA

Publications

  1. pmc Intratumoral immunotherapy of established solid tumors with chitosan/IL-12
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 33:697-705. 2010
  2. pmc Exercise enhances vaccine-induced antigen-specific T cell responses
    Connie J Rogers
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Vaccine 26:5407-15. 2008
  3. pmc The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines
    Kenneth W Hance
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:2387-96. 2009
  4. pmc Chitosan solution enhances the immunoadjuvant properties of GM-CSF
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, United States
    Vaccine 25:8673-86. 2007
  5. pmc Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12
    David A Zaharoff
    Laboratory of Tumor Immunology Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 69:6192-9. 2009
  6. pmc Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity
    Hasan Zeytin
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Interferon Cytokine Res 28:73-87. 2008
  7. pmc Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice
    Connie J Rogers
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Nutr 138:115-22. 2008
  8. pmc Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, United States
    Vaccine 25:2085-94. 2007
  9. pmc In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines
    Michael J Heffernan
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Biomaterials 32:926-32. 2011

Collaborators

Detail Information

Publications9

  1. pmc Intratumoral immunotherapy of established solid tumors with chitosan/IL-12
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 33:697-705. 2010
    ..Chitosan/IL-12 is a well-tolerated, effective immunotherapy with considerable potential for clinical translation...
  2. pmc Exercise enhances vaccine-induced antigen-specific T cell responses
    Connie J Rogers
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Vaccine 26:5407-15. 2008
    ..These results suggest that coupling moderate exercise with vaccination may enhance vaccine efficacy for the prevention and/or therapy of numerous diseases...
  3. pmc The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines
    Kenneth W Hance
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:2387-96. 2009
    ....
  4. pmc Chitosan solution enhances the immunoadjuvant properties of GM-CSF
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, United States
    Vaccine 25:8673-86. 2007
    ..We conclude that chitosan solution is a promising delivery platform for the sustained, local delivery of rGM-CSF...
  5. pmc Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12
    David A Zaharoff
    Laboratory of Tumor Immunology Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 69:6192-9. 2009
    ..Intravesical chitosan/IL-12 is a well-tolerated, effective immunotherapy that deserves further consideration for testing in humans for the management of superficial bladder cancer...
  6. pmc Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity
    Hasan Zeytin
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Interferon Cytokine Res 28:73-87. 2008
    ....
  7. pmc Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice
    Connie J Rogers
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Nutr 138:115-22. 2008
    ..05). These data suggest that ER and EX enhance some, but not all, components of the immune system and are likely working via different biological mechanisms to regulate NK and T-cell function...
  8. pmc Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, United States
    Vaccine 25:2085-94. 2007
    ..These mechanistic studies, taken together with the enhancement of a vaccine response, demonstrate that chitosan is a promising and safe platform for parenteral vaccine delivery...
  9. pmc In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines
    Michael J Heffernan
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Biomaterials 32:926-32. 2011
    ..The combination of chitosan and IL-12 also enhanced IgG2a and IgG2b antibody responses to OVA. Co-formulation of chitosan and IL-12 thus promoted the generation of a Th1 immune response to a model protein vaccine...